Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer
SourceGynecologic Oncology, 161, 3, (2021), pp. 787-794
Article / Letter to editor
Display more detailsDisplay less details
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.